TScan Therapeutics to Participate in the 5th Annual Evercore ISI HealthCONx Conference

Rhea-AI Summary

TScan Therapeutics, Inc. (Nasdaq: TCRX) announced participation in the 5th Annual Evercore ISI HealthCONx Conference on November 29, 2022, at 10:55 a.m. ET. The management will engage in a virtual fireside chat, which will be available via webcast on the company's website under the "Events and Presentations" section. An archived replay will be accessible for 90 days post-event. TScan is focused on developing T cell receptor-engineered therapies for cancer, targeting residual disease and relapse prevention in patients with hematologic malignancies.

WALTHAM, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that management will participate in a virtual fireside chat at the 5^th Annual Evercore ISI HealthCONx Conference on Tuesday, November 29, 2022 at 10:55 a.m. ET.

A webcast of the fireside chat will be available on the “Events and Presentations” section of the Company’s website at ir.tscan.com. An archived replay of the webcast will be available on the Company’s website for 90 days following the event.

About TScan Therapeutics, Inc.

TScan is a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The Company’s lead TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. The Company is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors. The Company has developed and continues to build its ImmunoBank, the Company’s repository of therapeutic TCRs that recognize diverse targets and are associated with multiple HLA types, in order to provide customized multiplexed TCR-T therapies for patients with a variety of solid tumors.

Contacts

Heather Savelle
TScan Therapeutics, Inc.
VP, Investor Relations
857-399-9840
hsavelle@tscan.com

Joyce Allaire
LifeSci Advisors, LLC
Managing Director
617-435-6602
jallaire@lifesciadvisors.com

FAQ

What is TScan Therapeutics' participation in the Evercore ISI HealthCONx Conference on November 29, 2022?

TScan Therapeutics will participate in a virtual fireside chat at the 5th Annual Evercore ISI HealthCONx Conference on November 29, 2022, at 10:55 a.m. ET.

Where can I watch the TScan Therapeutics webcast from the conference?

The webcast of TScan Therapeutics' fireside chat will be available on the company's website under the 'Events and Presentations' section.

How long will the TScan Therapeutics webcast be available after the conference?

An archived replay of the webcast will be available for 90 days following the event.

What therapies is TScan Therapeutics developing?

TScan is developing T cell receptor-engineered therapies for cancer treatment, including candidates TSC-100 and TSC-101 aimed at hematologic malignancies.

What is the focus of TScan Therapeutics as a biopharmaceutical company?

TScan Therapeutics focuses on developing TCR-engineered T cell therapies for cancer treatment.